{"bill": {"#text": "\n\t", "form": {"current-chamber": {"#tail": "\n\t\t", "#text": "IN THE HOUSE OF REPRESENTATIVES"}, "#text": "\n\t\t", "congress": {"#tail": "\n\t\t", "#text": "113th CONGRESS"}, "#tail": "\n\t", "legis-num": {"#tail": "\n\t\t", "#text": "H. R. 5854"}, "official-title": {"#tail": "\n\t", "@display": "yes", "#text": "To allow the importation, distribution, and sale of investigational drugs and devices intended for \nuse by terminally ill patients who execute an informed consent document."}, "session": {"#tail": "\n\t\t", "#text": "2d Session"}, "distribution-code": {"#tail": "\n\t\t", "@display": "yes", "#text": "I"}, "action": {"action-date": {"#tail": "\n\t\t\t", "@date": "20141211", "#text": "December 11, 2014"}, "#tail": "\n\t\t", "action-desc": {"#tail": "\n\t\t", "#text": "\n        ", "sponsor": {"#tail": " introduced the following bill; which was referred to the ", "#text": "Mr. Grayson", "@name-id": "G000556"}, "committee-name": {"#tail": "\n      ", "@committee-id": "HIF00", "#text": "Committee on Energy and Commerce"}}, "#text": "\n\t\t\t"}, "legis-type": {"#tail": "\n\t\t", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-House", "@key": "H", "@bill-type": "olc", "@dms-id": "H25B1A1780A254DD294233D3BE491E899", "@public-private": "public", "legis-body": {"#tail": "\n", "@style": "OLC", "section": {"@section-type": "section-one", "#tail": "\n  ", "text": {"#tail": "\n      ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " is amended by inserting after ", "@entity-type": "act", "#text": "Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act"}, "#text": "The ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " the following:", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "section 561", "@value": "Federal Food, Drug, and Cosmetic Act/s:561"}, {"#tail": ")", "@entity-type": "uscode", "#text": "21 U.S.C.\n\t\t\t 360bbb", "@value": "usc/21/360bbb"}], "@entity-type": "law-citation", "#text": "\n          "}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n\t\t\t", "#text": "Drugs and devices for use by terminally ill patients"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n      ", "#text": "."}, "#tail": "\n    ", "section": {"#tail": "\n        ", "enum": {"#tail": "\n          ", "#text": "561A."}, "header": {"#tail": "\n          ", "#text": "Drugs and devices for use by terminally ill patients"}, "subsection": [{"#tail": "\n          ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " prevents or restricts, and the\n\t\t\t ", "@entity-type": "act", "#text": "section 351 of the Public Health Service Act", "@value": "Public Health Service Act/s:351"}, {"#tail": " shall not implement or enforce any provision\n\t\t\t of law preventing or restricting, the importation, distribution, or sale\n\t\t\t of an investigational drug or device intended for use by a terminally ill\n\t\t\t patient in accordance with subsection (b).", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "#text": "Nothing in this Act or "}, "enum": {"#tail": "\n            ", "#text": "(a)"}, "header": {"#tail": "\n            ", "#text": "In general"}, "#text": "\n            ", "@id": "id9A6F0553FC2B479A925EBE69B750BFB8"}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "#text": "In order for an investigational drug or device to be intended for use in accordance with this\n\t\t\t subsection, such drug or device must be intended for use by a patient who\n\t\t\t has\u2014"}, "enum": {"#tail": "\n            ", "#text": "(b)"}, "header": {"#tail": "\n            ", "#text": "Patient requirements"}, "paragraph": [{"#tail": "\n            ", "text": {"#tail": "\n            ", "#text": "been diagnosed with a terminal illness by a licensed physician;"}, "enum": {"#tail": "\n              ", "#text": "(1)"}, "@id": "idF3CF6FAC3B9E455B96A21E61BF19A1CC", "#text": "\n              "}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "#text": "been informed by a licensed physician that no drug or device that is lawfully marketed in the\n\t\t\t United States is likely to cure the illness; and"}, "enum": {"#tail": "\n              ", "#text": "(2)"}, "@id": "id2277C9C60E7249798EA52E17526FB330", "#text": "\n              "}, {"#tail": "\n          ", "text": {"#tail": "\n              ", "#text": "executed a written informed consent document that states\u2014"}, "enum": {"#tail": "\n              ", "#text": "(3)"}, "#text": "\n              ", "@id": "id6A5FA53586F5434FAE2C626D0AE026C0", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "the known and potential risks and benefits of such drug or device; and"}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@id": "id6C789B2C5BC34CAFA416DE770B9A8CFA", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "#text": "any indications of the illness for which a drug or device is lawfully marketed, or for which\n\t\t\t treatment is otherwise available, in the United States."}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@id": "idB9510150094B430BB3FDF10C27FB8807", "#text": "\n                "}]}], "#text": "\n            ", "@id": "id979744153EF946C1BBE227938E60F83F"}, {"#tail": "\n        ", "text": {"#tail": "\n            ", "term": {"#tail": " means a drug or device that\u2014", "#text": "investigational drug or device"}, "#text": "In this section, the term "}, "enum": {"#tail": "\n            ", "#text": "(c)"}, "header": {"#tail": "\n            ", "#text": "Definition of investigational drug or device"}, "paragraph": [{"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ",\n\t\t\t ", "@entity-type": "act", "#text": "section 505", "@value": "Federal Food, Drug, and Cosmetic Act/s:505"}, {"#tail": ", or ", "@entity-type": "act", "#text": "510(k)", "@value": "Federal Food, Drug, and Cosmetic Act/s:510/ss:k"}, {"#tail": " or ", "@entity-type": "act", "#text": "515 of this Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:515"}], "#text": "has not yet been approved, licensed, or cleared for commercial distribution under ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ", and cannot otherwise be lawfully marketed in the United\n\t\t\t States; and", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n\t\t\t (", "@entity-type": "act", "#text": "section 351 of the Public Health Service Act", "@value": "Public Health Service Act/s:351"}, "@entity-type": "law-citation", "#text": "\n                  ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                ", "@entity-type": "uscode", "#text": "42 U.S.C. 262", "@value": "usc/42/262"}, "@parsable-cite": "usc/42/262", "#text": "\n                  ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n              ", "#text": "(1)"}, "@id": "idBC811F15C3FF4AE893D1966DCF6BA9B1", "#text": "\n              "}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "#text": "is or has been the subject of one or more clinical trials."}, "enum": {"#tail": "\n              ", "#text": "(2)"}, "@id": "id7E29FDAC133C4DE795C20398E2D67EB1", "#text": "\n              "}], "#text": "\n            ", "@id": "id5080A28F3BA24A6C8D5630A490A221E4"}], "#text": "\n          ", "@id": "id6A9FE5F1D87B412D806E869A3F12444D"}, "@display-inline": "no-display-inline", "#text": "\n        ", "@id": "idDE95FE7CFBEF4C7EB0C1902A91775AB3"}, "#text": "\n      ", "@id": "H08FD6F0EA8794569AADC3AD790FC68B5"}, "#text": "\n\t\t", "@id": "HD030454E17364C6AB2BF4C0D4308DB56"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2014-12-11"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 HR 5854 IH: To allow the importation, distribution, and sale of investigational drugs and devices intended for use by terminally ill patients who execute an informed consent document."}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. House of Representatives"}, "#text": "\n"}, "#text": "\n"}}}